New Blood: Former Novartis Exec Transitions to Rubius Therapeutics – Genetic Engineering & Biotechnology News (blog)
|
New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
Genetic Engineering & Biotechnology News (blog) It described a way to take a person's T cells— immune cells that recognize molecules on the surface of infected or cancer cells—and modify them to target tumors. These altered cells, known as chimeric antigen receptor T cells (CAR-T), could then be … |
